Two widely used medicines—doxycycline and carbimazole—will soon carry stronger safety warnings following a national review of adverse drug reaction reports. After examining patient-level safety data, regulators identified potential mental health symptoms linked to doxycycline and a rare but serious blood disorder associated with carbimazole.
CDSCO and DCGI Issue Directives
In separate communications issued this month, the Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI) directed all State and Union Territory licensing authorities to ensure that manufacturers update prescribing information and package inserts for both medicines. They also instructed companies to report compliance.
Through this step, regulators aim to enhance transparency and strengthen patient safety.
Doxycycline: Neuropsychiatric Symptoms Added
Doxycycline, commonly prescribed for respiratory infections, acne, sexually transmitted infections, urinary tract infections, and several vector-borne diseases, will now include explicit warnings about certain central nervous system side effects.
These newly listed symptoms include restlessness, anxiety, irritability, nervousness, and dizziness.
As reported by TOI, the decision follows a detailed assessment by the Pharmacovigilance Programme of India (PvPI), which reviewed adverse reaction reports and individual case safety data. The Signal Review Panel first examined the issue in March 2025. Subsequently, the Subject Expert Committee (SEC) on antimicrobial and antiparasitic drugs discussed the findings in January 2026 and endorsed updating the official prescribing documents.
Although gastrointestinal discomfort and photosensitivity were already recognized side effects of doxycycline, regulators have now formally expanded its safety profile to include neuropsychiatric reactions.
Carbimazole: Warning on Agranulocytosis
Meanwhile, regulators have directed manufacturers of carbimazole—commonly prescribed for hyperthyroidism, including Graves’ disease—to prominently warn about agranulocytosis.
Agranulocytosis is a rare but potentially life-threatening condition characterized by a sharp decline in white blood cells. As a result, patients become highly vulnerable to severe infections. Early warning signs include fever, sore throat, and unexplained infections.
The recommendation emerged from the 26th Signal Review Panel meeting and was later reviewed by the SEC on endocrinology and metabolism before regulators approved its inclusion in the prescribing information leaflet.
Experts Welcome Strengthened Pharmacovigilance
Dr. Rommel Tickoo, Director of Internal Medicine at Max Hospital Saket, stated that the move reflects a maturing pharmacovigilance system.
He noted that while both medicines remain safe and effective when used appropriately, clearer warnings help doctors and patients identify rare but important side effects early. In the case of carbimazole, he emphasized that prompt medical attention for symptoms such as fever or sore throat can be life-saving.
According to him, such regulatory actions strengthen patient safety without causing unnecessary alarm.
Implications for Patients and Clinicians
For patients, the updated package inserts will provide clearer information about potential risks. At the same time, the advisory reinforces the responsibility of clinicians to counsel patients about warning symptoms and to monitor treatment appropriately.
Overall, the strengthened warnings highlight India’s growing emphasis on proactive drug safety monitoring and informed clinical practice.